Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival.
Fiorella Murillo PerezStephanie IoannouIman HassanallyPalak J TrivediChristophe CorpechotAdriaan J van der MeerWillem J LammersPier Maria BattezzatiKeith D LindorFrederik NevensKris V KowdleyKaren SchmidtNora CazzagonAnnarosa FloreaniAndrew L MasonAliya GulamhuseinCyriel Y PonsioenMarco CarboneAna LleoMarlyn J MayoGeorgios N DalekosNikolaos K GatselisDouglas ThorburnXavier P D M J VerhelstAlbert ParésMaría Carlota LondoñoHarry L A JanssenInvernizzi PietroRaj VuppalanchiGideon M HirschfieldBettina E HansenCynthia Levynull nullPublished in: Liver international : official journal of the International Association for the Study of the Liver (2023)
We can identify patients for second-line therapy at six months using an ALP threshold of 1.9 × ULN, given that approximately 90% of these patients are non-responders according to POISE criteria.